What is the dosage and administration of cholestyramine powder for treating high cholesterol?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cholestyramine Powder: Dosage and Administration for High Cholesterol

For treating high cholesterol in adults, start with 4 grams of cholestyramine resin once or twice daily, then titrate to a maintenance dose of 8-16 grams daily divided into two doses, with a maximum of 24 grams daily. 1

Starting Dose and Titration

  • Initial dose: 1 pouch or 1 level scoopful (containing 4 grams anhydrous cholestyramine resin) once or twice daily 1
  • Maintenance dose: 8-16 grams daily divided into two doses 2, 1
  • Maximum dose: 24 grams daily (6 pouches or scoopfuls) 1
  • Increase doses gradually with lipid/lipoprotein assessment at intervals of at least 4 weeks 1

Timing and Administration

  • Administer at mealtime, though timing can be modified to avoid interference with other medications 1
  • The medication may be given in 1 to 6 divided doses per day, though twice daily is standard 1
  • Never take in dry form—always mix powder with at least 2-3 ounces of water or non-carbonated beverage 1
  • Can be mixed with highly fluid soups or pulpy fruits like applesauce or crushed pineapple 1

Expected Efficacy

  • Monotherapy: Achieves 10.4% LDL-C reduction versus placebo 2
  • Dose-ranging studies show 16.3%, 22.8%, and 27.2% LDL-C reductions with 5g, 10g, and 15g daily doses respectively 2
  • When combined with low- to moderate-intensity statins, provides an additional 10-16% LDL-C reduction 2
  • The majority of lipid-lowering effect occurs within 14 days of therapy 3

Critical Drug Interactions and Spacing

  • All other medications must be taken at least 1 hour before or 4 hours after cholestyramine to prevent impaired absorption 2
  • This is particularly critical for: cyclosporine, oral contraceptives, olmesartan, phenytoin, sulfonylureas, thyroid replacement therapy, and warfarin 2
  • UDCA (ursodeoxycholic acid) must be spaced at least 4 hours away from cholestyramine 2
  • For warfarin patients, monitor INR frequently during initiation and periodically thereafter 2

Common Adverse Effects and Management

  • Gastrointestinal effects: Constipation, dyspepsia, and nausea are most common 2
  • Vitamin deficiencies: May cause vitamin K and fat-soluble vitamin deficiencies; supplement oral vitamins at least 4 hours before cholestyramine 2
  • Triglyceride elevation: Monitor triglycerides as cholestyramine can increase levels and potentially cause pancreatitis 2, 3
  • Rare but serious: bowel obstruction, fecal impaction, esophageal obstruction 2

Contraindications and Precautions

  • Absolute contraindications: Complete biliary obstruction, history of serious hypersensitivity, triglycerides >500 mg/dL, history of hypertriglyceridemia-induced pancreatitis, bowel obstruction 2
  • Avoid in patients with gastroparesis or other GI motility disorders 2
  • Avoid in patients with history of major GI tract surgery with risk for bowel obstruction 2

Special Populations

Pediatric Use

  • For children 10-17 years with heterozygous familial hypercholesterolemia: 8-16 g/day orally divided into 2 doses 2
  • Use as monotherapy or in combination with statin when LDL-C remains ≥190 mg/dL or ≥160 mg/dL with positive family history of premature CVD 2
  • Supplement folate and vitamin D due to documented reductions during therapy 2

Pregnancy and Lactation

  • Considered safe to use during pregnancy and lactation 2
  • For cholestasis-associated pruritus in pregnancy: 4-16 g daily in divided doses, separated from other medications by at least 2 hours 2
  • Monitor PT/INR regularly as cholestyramine may exacerbate vitamin K deficiency in cholestatic patients 2

Cardiovascular Outcomes Evidence

  • The LRC-CPPT trial demonstrated a 19% reduction in risk (p<0.05) of definite CHD death and/or definite nonfatal MI in 3,806 asymptomatic middle-aged men treated for an average of 7.4 years 2
  • This remains the only bile acid sequestrant with proven cardiovascular mortality benefit 2

Practical Considerations

  • High pill burden and poor palatability are major barriers to compliance 2
  • Confectionery bar formulation shows equivalent efficacy to powder but offers no compliance advantage and may have slightly more GI side effects 3
  • Single daily dosing may be as effective as divided dosing and can improve compliance 4
  • When combined with HMG-CoA reductase inhibitors, lipid-lowering effects are enhanced 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.